CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 81 enrolled
Drug / intervention
Medtronic PrimeADVANCED Neurostimulator +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01112579
NCT01112579Phase 2Completed
CompareCT.gov

Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Heart Failure

Medtronic Cardiac Rhythm and Heart Failure·interventional·Posted Apr 28, 2010·Updated Oct 29, 2015

In Brief

A Phase 2 clinical trial evaluating Medtronic PrimeADVANCED Neurostimulator for Heart Failure. Completed, enrolled 81 participants across 19 sites in 8 countries.

Detailed Summary

The purpose of this study is to determine the feasibility of spinal cord stimulation (SCS) as a chronic therapy for systolic heart failure.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure
CountriesCanada, Czechia, Germany, Italy, Netherlands, South Africa, Sweden, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 28, 2010
Enrollment StartApr 1, 2010
Primary CompletionJan 1, 2014
Study CompletionApr 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 16.2 years ago

Interventions

Medtronic PrimeADVANCED Neurostimulatordevice

Heart failure therapy

Medtronic PrimeADVANCED Neurostimulatordevice

Medical management